Filing Details

Accession Number:
0001395064-21-000248
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-09 06:04:25
Reporting Period:
2021-12-07
Accepted Time:
2021-12-09 06:04:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1845337 Day One Biopharmaceuticals Inc. DAWN Pharmaceutical Preparations (2834) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1002637 Millennium Pharmaceuticals Inc 40 Landsdowne Street
Cambridge MA 02139
No No Yes No
1395064 Takeda Pharmaceutical Co Ltd 1-1, Nihonbashi-Honcho 2-Chome
Chuo-Ku, Tokyo M0 103-8668
No No Yes No
1716229 Takeda Pharmaceuticals U.s.a., Inc. 95 Hayden Avenue
Lexington MA 02421
No No Yes No
1771657 Takeda Ventures, Inc. 9625 Towne Centre Drive
San Diego CA 92121
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-12-07 128,745 $18.43 6,288,652 No 4 S Indirect See Explanation of Responses
Common Stock Disposition 2021-12-07 58,190 $19.50 6,230,462 No 4 S Indirect See Explanation of Responses
Common Stock Disposition 2021-12-08 110,338 $18.03 6,120,124 No 4 S Indirect See Explanation of Responses
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Explanation of Responses
No 4 S Indirect See Explanation of Responses
No 4 S Indirect See Explanation of Responses
Footnotes
  1. Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.97. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
  2. This statement is being filed jointly by Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A. Inc., Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc.
  3. Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 6,062,900 shares of Common Stock held by Millennium Pharmaceuticals, Inc. and 57,224 shares of Common Stock held by Takeda Ventures, Inc. Millennium Pharmaceuticals, Inc. and Takeda Ventures, Inc. are each direct, wholly owned subsidiaries of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%).
  4. Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. may be deemed to share voting and dispositive power over the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. Each of Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A. Inc. disclaims beneficial ownership of the shares held by Takeda Ventures, Inc. and Millennium Pharmaceuticals, Inc. except to the extent of their pecuniary interests therein.
  5. Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $19.00 to $19.88. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
  6. Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.47. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.